High efficiency reprogramming of fibroblasts into cardiomyocytes
AssigneeThe Regents of the University of Colorado, a body corporate
InventorsKunhua Song, Yuanbiao Zhao, Pilar Londono, Timothy McKinsey
Life of this patent
Estimating the term…
Abstract
Pro-fibrotic signaling potently antagonizes cardiac reprogramming. Inhibition of pro-fibrotic signaling using small molecules that target the transforming growth factor-β/SMAD, or Rho kinase leads to conversion of approximately 60% of fibroblasts into beating cardiomyocytes. Conversely, over-activation of these pro-fibrotic signaling networks inhibits cardiac reprogramming. Using the disclosed methods, fibroblasts are converted to spontaneously contracting cardiomyocytes in less than two weeks.
Claims35
A composition comprising one or more vectors for in vivo gene delivery, wherein said one or more vectors comprise one or more expression cassettes encoding GATA4, MEF2C, and Tbx5, and also encoding one or more of miR-1 and miR-133.
One or more expression cassettes encoding GATA4, MEF2C, Tbx5, and a microRNA selected from one or more of miR-1 and miR-133.
A combination of therapeutics comprising GATA4, MEF2C, Tbx5, and a microRNA or microRNAs selected from one or more of miR-1 and miR-133.
Dependencies are inferred from the claim text.